NCD

New Initiative Launches to Address Neglected Global Health Crisis of Alcohol Harms

Retrieved on: 
Tuesday, November 1, 2022
Marketing, Chicago, World Health Organization, Population, GAPA, CEO, School, Health, GiveWell, Policy, Population health, Tobacco, Data collection, Injury, Research, Casswell station, Liver disease, WHO, Sport, Homicide, Degenerative disease, Disease, World, SAFER, Death, COVID-19, Government, Public health, Tax, Tuberculosis, NEW, University, Drinking, Assault, Learning, Cancer, Non-communicable disease, Trauma, International Organisation of Good Templars, HIV/AIDS, UIC, Senior, Falls, Environment, Solution, NCD, Publishing, Suicide, Drug, Soft drink, Pharmaceutical industry, Alliance

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- Alcohol consumption is a top-ten driver of death, illness and injury, with wide-ranging social and economic harms. Many of the harms related to alcohol disproportionately affect young adults, and surveys from multiple countries suggest that the Covid-19 pandemic has further increased drinking. Today, Vital Strategies announced RESET Alcohol – a groundbreaking new $15 million initiative to reduce alcohol-related harms in hard-hit countries through policy change.

Key Points: 
  • Today, Vital Strategies announced RESET Alcohol a groundbreaking new $15 million initiative to reducealcohol-related harms in hard-hit countries through policy change.
  • Public health work on alcohol isvastly underfunded relative to the issue's burden, and the philanthropic award that founds RESET Alcohol roughly doubles existing global funding.
  • RESET Alcohol is a collaboration of six global organizations: Vital Strategies, which is leading the initiative; Movendi International ; the University of Illinois Chicago ; the Global Alcohol Policy Alliance (GAPA); the Non-Communicable Disease (NCD) Alliance ;and World Health Organization (WHO).
  • Learn more about RESET Alcohol here: https://www.vitalstrategies.org/programs/alcohol-policy/
    RESET Alcohol brings together national governments, civil society, and global leaders to advance policies from the World Health Organization's SAFER package for reducing the health, social and economic harms of alcohol.

New Initiative Launches to Address Neglected Global Health Crisis of Alcohol Harms

Retrieved on: 
Tuesday, November 1, 2022
Marketing, Chicago, World Health Organization, Population, GAPA, CEO, School, Health, GiveWell, Policy, Population health, Tobacco, Data collection, Injury, Research, Casswell station, Liver disease, WHO, Sport, Homicide, Degenerative disease, Disease, World, SAFER, Death, COVID-19, Government, Public health, Tax, Tuberculosis, NEW, University, Drinking, Assault, Learning, Cancer, Non-communicable disease, Trauma, International Organisation of Good Templars, HIV/AIDS, UIC, Senior, Falls, Environment, Solution, NCD, Publishing, Suicide, Drug, Soft drink, Alliance

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- Alcohol consumption is a top-ten driver of death, illness and injury, with wide-ranging social and economic harms. Many of the harms related to alcohol disproportionately affect young adults, and surveys from multiple countries suggest that the Covid-19 pandemic has further increased drinking. Today, Vital Strategies announced RESET Alcohol – a groundbreaking new $15 million initiative to reduce alcohol-related harms in hard-hit countries through policy change.

Key Points: 
  • Today, Vital Strategies announced RESET Alcohol a groundbreaking new $15 million initiative to reducealcohol-related harms in hard-hit countries through policy change.
  • Public health work on alcohol isvastly underfunded relative to the issue's burden, and the philanthropic award that founds RESET Alcohol roughly doubles existing global funding.
  • RESET Alcohol is a collaboration of six global organizations: Vital Strategies, which is leading the initiative; Movendi International ; the University of Illinois Chicago ; the Global Alcohol Policy Alliance (GAPA); the Non-Communicable Disease (NCD) Alliance ;and World Health Organization (WHO).
  • Learn more about RESET Alcohol here: https://www.vitalstrategies.org/programs/alcohol-policy/
    RESET Alcohol brings together national governments, civil society, and global leaders to advance policies from the World Health Organization's SAFER package for reducing the health, social and economic harms of alcohol.

Global Alzheimer’s Platform Foundation (GAP) Celebrates Lecanemab’s Positive Clinical Trial Results

Retrieved on: 
Wednesday, September 28, 2022
African Americans, Global, Lists of diseases, Memory, Safety, Center, Incidence, Medicare, Brain, FDA, NCD, Food, National coverage determination, Alzheimer's disease, ARIA, CMS, Problem solving, Treatment, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Air gap (networking), Amyloid, Centers for Medicare & Medicaid Services, Dwyer, GAP, Hobby, Dementia, GLOBE, Orientation, Pharmaceutical industry, Medical imaging, Eisai

WASHINGTON, DC, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Today, the Global Alzheimers Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimers disease, marking an enormous milestone for millions of people living with Alzheimers disease.

Key Points: 
  • WASHINGTON, DC, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Today, the Global Alzheimers Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimers disease, marking an enormous milestone for millions of people living with Alzheimers disease.
  • This study met all its endpoints, unprecedented in Alzheimers; its a landmark day, said John Dwyer, GAP president.
  • These results will change the lives of those with Alzheimers, and I am proud that GAP and GAP-Net clinical research trial sites were integral in conducting this groundbreaking study, Dwyer added.
  • The Global Alzheimers Platform Foundation (GAP) is a patient-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials.

Alzheimer's Association Statement on Lecanemab Phase 3 Topline Data Release

Retrieved on: 
Wednesday, September 28, 2022
Adaptive clinical trial, Safety, Center, National coverage determination, Medicare, FDA, NCD, Food, Alzheimer's Association, CMS, Clinical trial, Learning, Treatment, Center for Medicare and Medicaid Innovation, Eisai, MCI, Amyloid, Centers for Medicare & Medicaid Services, Method, Dementia, CLARITY, Research, Association, Multimedia, Biogen, Food and Drug Administration Amendments Act of 2007, Disease, Pharmaceutical industry, Residential care, Alzheimer's disease

We look forward to learning more about data from CLARITY AD at the Clinical Trials in Alzheimer's Disease (CTAD) meeting in November, including data on participant safety and representation.

Key Points: 
  • We look forward to learning more about data from CLARITY AD at the Clinical Trials in Alzheimer's Disease (CTAD) meeting in November, including data on participant safety and representation.
  • If those data are consistent with what we saw today regarding efficacy and safety, we strongly support FDA approval and full coverage.
  • The Alzheimer's Association has long been committed to advancing all potential treatment avenues , and exploring methods for combining diverse approaches into combination therapies.
  • The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research.

Heads of State Commit to Noncommunicable Disease Global Compact to Save 50 Million Lives by 2030

Retrieved on: 
Wednesday, September 21, 2022
Safety, World, Non-communicable disease, Investment, UNGA, Drowning, Leadership, Education, Public health, Tax, COVID-19, Newborn Screening Saves Lives Act of 2007, NCD, NEW, United Nations, Malaysian Industry-Government Group for High Technology, Degenerative disease, Life expectancy, Ambassador, Chronic lung disease, Partnership, YouTube, Sustainable Development Goals, Diabetes, Instagram, Tobacco, Cardiovascular disease, World Health Organization, WHO, TikTok, SDG, Death, Income, United Nations General Assembly, Health, Twitter, Infection, City, LinkedIn, Bloomberg, Risk, Cancer, State, Gallup, Bloomberg Philanthropies, Pinterest, Johns Hopkins University, Awareness, First Nations in Ontario, Pharmaceutical industry, Dietary supplement, Injury, Facebook, Environment

GENEVA and NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Today, Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), launched a new report calling on global leaders to take urgent action on noncommunicable diseases (NCDs), responsible for 17 million premature deaths every year.

Key Points: 
  • To accelerate action, Dr. Tedros renewed the two-year appointment of Michael R. Bloomberg as WHO Global Ambassador for Noncommunicable Diseases and Injuries.
  • This follows the launch of a Global NCD Compact earlier this year by Ghana and Norway.
  • Noncommunicable diseases like heart disease, cancer, diabetes, and lung disease now outnumber infectious disease as the top killers globally.
  • Recently, Bloomberg Philanthropies invested an additional $115 million in global public health nonprofit Resolve to Save Lives bringing its total investment to $215 million to continue preventing deaths from heart disease.

Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer

Retrieved on: 
Saturday, September 10, 2022
Research, Technology, Medical Devices, Genetics, Software, Biotechnology, Health, Science, Oncology, Artificial Intelligence, Liquid biopsy, EMSO, Breast cancer, CRC, Machine learning, RNA, Diagnosis, Oncology, Poster, NCD, Technology, Colorectal cancer, Cancer, Bio, Blood, Biomarker, DNA, European Society for Medical Oncology, Recurrence, Health, Publication, ESMO, Patient, Artificial intelligence, Neoplasm, UCSF, Medical imaging, Exai

Exai has created a proprietary library of >250,000 oncRNAs found in several types of cancer.

Key Points: 
  • Exai has created a proprietary library of >250,000 oncRNAs found in several types of cancer.
  • Exai Bio is thus positioned to improve patient care by developing a variety of liquid biopsy blood tests for CRC, including for early detection and monitoring of residual disease or recurrence.
  • This work demonstrates that Exai Bio can measure novel biomarkers in blood-derived samples to accurately predict colorectal cancer, including the earliest-stage and smallest tumors.
  • The companys proprietary RNA and artificial intelligence-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.

Prostate Cancer Nuclear Medicine Diagnostics Markets, 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 1, 2022
Oncology, Health, Consumer, Seniors, Radiology, Men, Pharmaceutical, Prostate cancer, COVID-19, Medicaid, PET, Cancer, Centers for Medicare & Medicaid Services, Nuclear medicine, SPECT, Skin cancer, CMS, Health, Diagnosis, Common, National coverage determination, Health insurance, Journal, Adoption, PCA, Center, Positron emission tomography, CAGR, American Pet Products Association, NCD, Growth, The Journal of Nuclear Medicine, Efficiency, Radiology, Medical imaging, Medicare

The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028.

Key Points: 
  • The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028.
  • Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.
  • Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET.
  • Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics.

Insights on the Nasal Drug Delivery Mode Global Market to 2028 - Size, Share, Outlook and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 1, 2022
Pharmaceutical, Health, Medical Devices, Technology, Ageing, Paranasal sinuses, Nasal administration, Nose, Distribution, Asthma, Dosage form, Chronic obstructive pulmonary disease, US, Region, Absorption, Prevalence, CAGR, COPD, Container (type theory), NCD, Growth, Industry, Marketing, Adoption, AAFA, Pharmaceutical industry

Drug delivery refers to the technology utilized to present the drug to the desired body site for drug release and absorption.

Key Points: 
  • Drug delivery refers to the technology utilized to present the drug to the desired body site for drug release and absorption.
  • The global nasal drug delivery mode market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal drug delivery mode market.
  • Global Nasal Drug Delivery Mode Market, By Therapeutic Application:

Nuo Therapeutics Provides Corporate and Business Update

Retrieved on: 
Tuesday, August 30, 2022
Security (finance), Chief financial officer, Centers for Medicare & Medicaid Services, Sumathi Best Television Current Reporting Award, PRP, Sale, California Pacific Medical Center, SEC, U.S. Securities and Exchange Commission, Mouth ulcer, GLOBE, Medicare, Prevalence, FDA, Company, Population, Diabetes, NCD, OTCQB, Patient, Nature, Financial services, Pharmaceutical industry, Risk management, Nuo, Infineon AURIX

HOUSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo” or the “Company”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced today an initial corporate and business update since re-establishing fully available commercial operations in the second quarter of this year.

Key Points: 
  • This investment will allow Nuo to deliver effective clinical outcomes in the treatment of chronic wounds, while substantially advancing the business opportunity and positioning Nuo for future success.
  • While being focused on business execution presently, Nuo believes that an uplisting to a national securities exchange will be a viable option at the appropriate time.
  • Nuo Therapeutics, Inc. is a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape.
  • The Company expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

Global Vital Signs Monitoring Devices Market Report to 2030 - Increasing Incidence Rate of Chronic Diseases is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 23, 2022
Medical Devices, Health, Statistics, CVD, COVID-19, Technology, Cancer, Application, Ageing, WHO, Death, Time, Estimation, Degenerative disease, Lists of diseases, World, USD, Vital signs, Adoption, Prevalence, CAGR, Diabetes, NCD, Marketspace, Industry, Growth, Profile, A&D Company, Patient, World Health Organization, Medical device

Moreover, the rising elderly population around the globe contributes substantially towards the rise in the growth rate of the vital signs monitoring devices market.

Key Points: 
  • Moreover, the rising elderly population around the globe contributes substantially towards the rise in the growth rate of the vital signs monitoring devices market.
  • The global vital signs monitoring devices market report answers questions such as:
    What is the market size and forecast of the global vital signs monitoring devices market?
  • What modes and strategic moves are considered favorable for entering the global vital signs monitoring devices market?
  • The global vital signs monitoring devices market is segmented into measuring parameters, application, form factor and end user.